NK Cell immunotherapy muIndia
NK Cell immunotherapy muIndia inopihwa nemamwe makambani ekurapa maseru uye zvipatara izvozvi. NK Cell immunotherapy yekurapa kenza inodzokororwa uye yakaoma iri kuwana mukurumbira nezuva. Varwere vawanda vava mazuva ari kuenda kunorapwa immunotherapy. NK Cell therapy inowanikwa kuve inoshanda zvakanyanya mukunonoka kurapwa kwegomarara. Saka varwere vari muchikamu chekupedzisira chegomarara vanogona kuedza kurapwa uku. NK Cell therapy mukati yave kuwanikwa mukati India. Unoziva ruzivo nezve kurapwa uye mutengo tifonere pa + 91 96 1588 1588 kana kunyorera ku cancerfax@gmail.com.
Masero emagetsi
Mushure mezviuru zvemakore ekushanduka-shanduka, muviri wemunhu wakagadzira yakaomesesa yekudzivirira, yakamisa simba rekudzivirira region, inochengetedza nhamba huru yevarwi vepamusoro, uye inogara ichitidzivirira kubva pakurwiswa kwegomarara. Mwongo ndiwo hwaro hweImmune Corps. Pano, masero ehematopoietic stem anosiyanisa kuva varwi vakasiyana-siyana vane mabasa akasiyana. Vane nharaunda yavo yemauto uye mabasa ebasa. Parizvino, mauto matatu ekudzivirira immune system uye avo vari pasi pavo ndeaya anotevera:
1. Core Corps: Lymphocytes
T-lymphocytes, thymus-dependent lymphocytes, ndiwo ma lymphocytes makuru muropa uye kutendererazve.
B-lymphocytes: Masero anokura mu bursa kana nhengo yaro yakaenzana (bone marrow). Vanogona kusiyanisa mumasero eplasma anobudisa antibodies kana yamutswa na antigen.
NK masero, LAK masero haadi antigen-sensitizing kuuraya maitiro.
2. Auxiliary Legion: Antigen Presenting Cell
Monocyte-macrophage phagocytosis uye kuuraya mhedzisiro, iripo TD antigen, tanga immune immune, anti-tumor athari, secrete biologically inoshanda murevereri.
Maseru eDC iboka remasero akasiyana ane akasimba kwazvo antigen kuratidza basa, uye ndiwo ega antigen akazara-akazara maseru anogona kushandura maT masero ekutanga.
3.Mamwe immune cell legion
Neutrophils, eosinophils / basophils uye mast masero, maplatelet, masero matsvuku eropa.
Chii chinonzi NK masero?
Whistler-NK masero ari immune system
Hondo yekudzivirira muviri mumuviri wedu yakangofanana nehondo yekurwisa muvengi inoratidzwa mufirimu. Zvinoda mauto matatu kuti vagovane mabasa avo zvakajeka, vagadzire hurongwa hwehondo hwakasimba, uye vashande pamwechete kutsakatisa muvengi.
Muhondo yekurwisa cancer maseru, NK masero ndiwo anotyisa kwazvo "whistleblower".
It not only bears the brunt, it is the first to reach the tumarara microenvironment to directly kill cancer cells, and it also sounds the horn of war, secretes secret weapon chemokines, and recruits dendritic cells (CD103 + DC), which is equivalent to telling other immune legions in the body Come and cooperate. The activated dendritic cells then carry tumor antigens to the lymph nodes, presenting the characteristics of the cancer cells to the killer T cells. T cells rushed to the battlefield to kill cancer cells with NK cells.
Chii chinonzi NK Cell therapy?
Zita rakazara remasero eNK masero anonzi Natural Killer cells (NK), uye iboka rechitatu remalymphocytes akasungwa neT uye B masero mu core cell army. NK masero aripo muropa revanhu uye "vanotanga kupindura". Zvakafanana nemupurisa wepatrol anga ari pabasa mumutumbi. Sezvo ropa richimhanya-mhanya, panguva yekufambisa, NK masero anoramba achisangana nemamwe masero. Kamwe abnormalities awanikwa mumuviri Ibva warasa maseru. Vakarwisa uye vakaburitsa cytotoxic zvimedu zvine perforin uye granzyme pane yakanangwa sero membrane masero eT asati aiswa, zvichikonzera cancer maseru kuti azviparadze. Ivo zvakare vanobvisa kutenderera cancer stem masero uye kubatsira kudzivirira metastasis.
Kutanga, igadziriro yomuzvarirwo yomuviri womunhu inodzivirira zvirwere. Zvechokwadi imhare iri kufamba mberi. Anenge ese bundu masero acharwiswa ne NK masero zviri nani.
Chechipiri, "whistleblower" mune immune system ine mhinduro panguva yemamiriro ezvinhu. Kana iyo "muvengi mamiriro" awanikwa, inokurumidza "inoshuma" uye inotanga kudzivirira kwekudzivirira uye kuuraya kwekudzivirira kwezvirwere zvemuviri wese.
Chechitatu, ine wide-spectrum antitumor effect, haidi kucherechedzwa kwebundu, uye haina kuganhurirwa neyakakura histocompatibility complex (MHC) inhibitory chiitiko pasero. Nguva yekutanga-yekutanga ndiyo inokurumidza, uye masero eT anoda kuratidzwa antigen asati akwanisa kusiyanisa "muvengi nemuvengi".
Naizvozvo, iyo yekuuraya kenza ine simba.
Matanho matatu makuru ekuuraya cancer eNK masero
NK masero anoita basa rinokosha mumutsara wekutanga wekudzivirira kubva kune kenza. NK masero ane matatu anticancer mhedzisiro:
Chekutanga, kuuraiwa kwakananga kwemabundu masero. Uraya masero ebundu ne-post-perforin uye granzymes kana nekufa zvinogamuchirwa;
Chechipiri, kuburikidza nekubudiswa kwe cytokines uye chemokines kuti iite basa rekugadzirisa sero rekudzivirira muviri, kuita masero eT uye mamwe maitiro ekuuraya;
Chechitatu, ADCC mhedzisiro (antibody-inotsamira cell-mediated cytotoxic effect) inoumbwa. Kana B sero rawana sero regomarara, rinosiya chinyararire iyo IgG antibody pasero regomarara sechiratidzo chekuyeuchidza NK masero. Pavanoona iyi yakanyorwa kuti NK cell, vanoona imwe kuuraya imwe. Nerubatsiro rwemacrophages uye B masero, tsika yekuuraya cancer yakawedzera zvakanyanya.
Unogona kuda kuverenga: T Cell uye NK Cell kurapwa muIndia
NK cell-yakavakirwa immunotherapy
Kunyange zvazvo vachikwanisa kukurumidza kudzivirira uye kurwisa zvakananga masero emamota, nhamba yemasero eNK mumuviri wemunhu idiki, inotora 10% chete yemasero machena eropa. Uye chidzidzo chacho chakawana kuti mushure memakore makumi maviri nemashanu, vanhu vakaderedza hutachiona uye vakaderedza nhamba yeNK masero. Nhamba uye basa re NK masero muvarwere vane bundu uye varwere vepashure-bundu vakachinja kune imwe nhanho, uye havagone kuita basa rinoshanda mukurwisa kenza.
Researchers are now developing multiple methods to release NK cell activity against tumors, thereby increasing the efficacy and specificity of NK cell-based therapies. At present, there are three main types of NK cell strategies for tumor immunotherapy munyika.
01.In vitro activated autologous kana allogeneic NK cell therapy
Parizvino, mudzimba nepasirese zvinotariswa pa "adoptive" NK cell therapy ndeyekuunganidza NK masero kubva kune vanopa hukama hwepedyo uye kuvabaya muvarwere. Izvi zvakaratidza kuve zvakachengeteka, uye kusiyana neT-cell therapy, NK masero haakonzeri chirwere chegraft-versus-host mumatishu anogamuchira.
02.Kubatanidza NK masero uye monoclonal antibodies (akadai seimmune checkpoint inhibitors) kuita kuti antibody-specific cytotoxicity.
Kubatanidza cheki yekurapa nemamwe NK-directed immunotherapy inogona kunanga akawanda marudzi emamota ayo parizvino asingapindure kune aripo marapirwo.
Kunyange zvazvo nzira yekuuraya yemasero eNK kurwisana nemamota isiri yakananga uye isingatsamiri pakuzivikanwa kwema antigens ane bundu, kunewo kushandiswa kana kudzvinyirira nzira dzekuongorora zvirwere. Ligands inogona kuratidzwa nebundu masero kurwisa NK cell immune checkpoints inogona kutadzisa NK cell-mediated bundu cell lysis. Naizvozvo, kudzikamisa inhibition iyi, nhevedzano ye inhibitory immune checkpoints kurwisa bundu-NK masero ari kugadzirwa maAntibodies.
Zvakadai se cetuximab inopesana neEGFR, cetuximab inogona kumisa iyo ADCC mhedzisiro yeNK masero uye kutanga inogadzirisa immune immune re NK masero.
In addition, studies have found that PD-1 in NK cells is highly expressed in several cancers, including head and neck cancer, thyroid cancer, Hodgkin’s lymphoma (HL), digestive tract cancer (esophageal cancer, liver cancer, colorectal cancer, gastric cancer and biliary cancer ), Breast cancer, Kaposi’s sarcoma, renal cell carcinoma and multiple myeloma. Recent studies have shown that when PD-L1-negative tumors respond to anti-PD-L1 treatment, this effect may be mediated by PD-L1 + NK cells. PD-L1 + NK cells treated with anti-PD-L1 showed enhanced activation and effector function.
03.Gadzira CAR-NK cell immunotherapy
Chimeric antigen receptor-yakagadziridzwa NK masero: inogona kuvandudza zvakanyanya
e iyo chaiyo yeNK cell efficacy. Iyi pfungwa yakafanana nekuvakwa kweCAR-T: CAR inosanganisira extracellular recognition domain (yakadai scFv) kuziva tumor-specific antigens; transmembrane domain, uye intracellular signing domain (CD3ζ chain) inogona kupinza NK masero.
Ndevapi varwere vakanakira NK Cell therapy?
Parizvino, mudzimba uye kune dzimwe nyika NK cell immunotherapy yakadzidzwa zvakanyanya. Zvemukati neJapan NK masero anonyanya kunangwa pamamota akasimba, ukuwo American NK therapy inonyanya kunangana nemamota eropa.
Cellular immunotherapy inogona kuenderana nechero nhanho yegomarara, senge:
1. Varwere vanotarisira kushandisa cellular immunotherapy kuti vavandudze hutachiona, kubvisa masero emukenza akasara, kudzivirira kudzokorora, uye kurarama kwenguva refu mushure mekuvhiyiwa kubviswa kwemaronda.
2. Mushure meradiotherapy uye chemotherapy, varwere vane hutachiwana hushoma uye migumisiro yakajeka (yakadai sokurasikirwa kwechido, kusvotwa, kurasikirwa kwebvudzi, kuputika kweganda, nezvimwewo) vanotarisirwa kuwedzera kushanda kwechemoradiotherapy.
3. Varwere vanotya migumisiro yeradiotherapy uye chemotherapy uye vanotarisira kushandisa nzira dzakasiyana-siyana dzokurapa kuti vawane maitiro ekurapa.
4. Varwere vane masero emukenza wepamusoro akapararira mumuviri wose, asi varwere vane nzira dzekurapa dzakagadziriswa havana kukwanisa kuita kudaro, vachitarisira kuwedzera kurarama uye kuvandudza mararamiro ehupenyu.
Mapoinzi akakosha: Cellular immunotherapy haina mhedzisiro iri pachena pakuderera kwemamota muvarwere vane kenza yepamusoro. Mhedzisiro yevarwere vane cancer yakakwira ndeyekuchengetedza hupenyu uye kurebesa hupenyu. Iyo yakanyanya kukodzera sero immunotherapy ichangobva kuvhiyiwa. Semushonga we adjuvant mushure mekuvhiyiwa, kudzvinyirira kudzokorora uye kuchengetedza kurapwa kwekutanga kwevarwere vane kenza yekutanga-kusvika-yepakati-danho; yakasanganiswa nekemotherapy, zvinodhaka zvakanangwa, PD1 inhibitors uye mamwe marapirwo, mhedzisiro ichava nani.
Cellular immunotherapy haina kukodzera kune vese varwere vegomarara. Kufanana nesarcoma yakatambura naWei Zexi, ibundu risingawanzo kuve nehupamhi hwehutsinye. Parizvino hapana kurapwa kwakanaka munyika. Naizvozvo, cellular immunotherapy haikodzeri. . Naizvozvo, ndapota ita shuwa kuti iwe, nhengo dzemhuri yako, uye shamwari dzako dziri kure neruzivo rwenhema paInternet. Usati wasarudza kugamuchira kurapwa, unofanirwa kuongororwa nenyanzvi muchipatara chenguva dzose uye chine chiremera chegomarara. Uye zvakare, mutengo we cellular immunotherapy wakakwira, kwete Mhuri dzese dzinogona kuzvigamuchira. Munhu wose anofanira kusarudza nokungwarira maererano nemamiriro eupfumi emhuri.
Kunyangwe iwe usingakwanise kubvuma kurapwa kwepamusoro uku, munhu wese haafanire kuve nemanzwiro asina kunaka. Ndinonzwa kuti matekinoroji matsva aya akagadzirirwa vapfumi, uye varombo vanofanira kumirira rufu kana vabatwa negomarara. Mafungiro aya haana kunaka zvachose. Tese tinoziva kuti mafungiro akanaka ndicho chombo chinoshanda kukunda gomarara. Varwere vakawanda vakapedza marudzi ose ebasa nedzvinyiriro dzoupenyu pashure pokunge varwara nekenza, vakabvisa ruvengo rwavo kuvamwe vanhu vakavapoteredza, vakadzidza kukanganwira, vakadzidza kuonga, uye vakachinja chose chose mararamiro avo. Kudya chikafu chine hutano, kurovedza muviri nguva dzose, kushanda nguva dzose uye kuzorora, uye kugadzirisa mafungiro ako kunogonawo kuwana hupenyu hurefu, izvo zvakakosha.
Ndezvipi zvipatara zvinopa NK Cell kurapwa muIndia?
NK Cell therapy tekinoroji yesero uye iyi inopihwa nemakambani ekurapa maseru. Parizvino pane kambani imwe chete yakatenderwa iri kupa NK Cell kurapwa muIndia. Kuti uwane ruzivo pamusoro pekukodzera kwemurwere kuNK Cell therapy ndapota fona pa + 91 96 1588 1588 kana kutumira varwere mishumo yekurapa kune cancerfax@gmail.com.
Chiremba akanakisa weNK Cell kurapwa muIndia
Sezvambotaurwa NK cell therapy muIndia inopihwa nemakambani ekurapa maseru uye vane timu yavo yevanachiremba vanoongorora hutano hwemurwere panguva yekurapa.
Ndeipi mutengo weNK Cell therapy muIndia?
Mutengo weNK cell therapy muIndia zvinoenderana nerudzi uye huwandu hwegomarara mumurwere. Nekudaro kune referensi Mutengo weNK Cell kurapwa muIndia unogona kusiyana pakati $ 9000-12000 USD.
Ndeipi maitiro eNK Cell therapy muIndia?
Maitiro uye nhamba yeinfusions zvinoenderana nemunhu kumunhu uye chiyero & rudzi rwegomarara. Ndokumbira utumire marepoti ekurapa kune iri pazasi email uye nhamba yeWhatsApp uye isu tichadzoka nehurongwa hwemunhu hwekurapa.
Kuti uzive nezve NK Cell therapy fona + 91 96 1588 1588 kana kutumira marepoti ekurapwa kwemurwere kune cancerfax@gmail.com.